- Patients with hematological malignancies and depression at baseline demonstrated inferior survival, regardless of whether they remained depressed or recovered from depression.
Why this matters
- 12%-33% of patients with hematological malignancies demonstrate symptoms of depression.
- Study to investigate depressive symptoms in 255 patients with newly diagnosed malignant lymphoma (n=184) or multiple myeloma (n=71) before chemotherapy (T1) and 1 month later (T2) using the Patient Health Questionnaire-9 (PHQ-9).
- Patients with depressive symptoms were subdivided as follows:
- New depressive symptoms at T2 (new onset; n=19).
- Remission of depressive symptoms at T2 (remission; n=38).
- Persistent depressive symptoms from T1 to T2 (persistent; n=26).
- Funding: Japanese Society for the Promotion of Science; others.
- Inferior OS in patients with vs without depression (aHR, 2.43; 95% CI, 1.43-4.12; P<.001>
- Adjusted HRs for OS (never-depressed as reference group):
- New onset: aHR, 1.91; 95% CI, 0.77-4.75; P=.166.
- Remission: aHR, 2.98; 95% CI, 1.55-5.74; P=.001.
- Persistent: aHR, 2.17; 95% CI, 1.01-4.68; P=.047.
- Shorter OS in depressed vs never-depressed patients by malignancy:
- Malignant lymphoma: aHR, 2.72; 95% CI, 1.30-5.71; log-rank P=.004.
- Multiple myeloma: aHR, 2.39; 95% CI, 0.94-6.08; log-rank P=.050.
- Patient-reported data via questionnaires; no interview-based assessments.